GSK willing to pay big for Anacor's anti-infectives

GlaxoSmithKline is buying into Anacor Pharmaceuticals' research work, inking a deal to in-license boron-containing small molecule anti-infective drug candidates. In a distinctly back-loaded pact, Anacor gets $12 million up front and a $10 million equity investment with hundreds of millions of dollars in potential milestones for each of a slate of drug prospects. Glaxo gets to pick experimental products aimed at up to four discovery targets, with an option to license therapies after proof-of-concept. A successful development program can earn Palo Alto, CA-based Anacor up to $331 million in milestone payments on each of those drug candidates. Ancora was a 2007 Fierce 15 company.

- see the release on the deal

Related Article:
Anacor forges $625M pact with Schering-Plough. Report
Riled investors look for big changes at GSK. Report
GSK chief outlines big plans in R&D. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.